Joyce O’Shaughnessy, MD
Advertisement
Articles by Joyce O’Shaughnessy, MD
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Marina Sharifi,Kristine Rinn,Wassim McHayleh,Rinat Yerushalmi,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Bartomeu Piza Vallespir,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Eva Ciruelos,Ji-Yeon Kim,Elena López-Miranda,Elia Seguí,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Alessandro Di Sanzo,Paula Muñoz Romero,Bartomeu Piza Vallespir,Manuel Dominguez,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
ByFatima Cardoso,Joyce O’Shaughnessy, MD,Heather McArthur, MD, MPH,Peter Schmid, MD,Javier Cortés, MD,Nadia Harbeck, MD, PhD,Melinda L. Telli, MD,David W. Cescon,Peter A. Fasching,Zhimin Shao,Delphine Loirat,Yeon Hee Park,Manuel Gonzalez Fernandez,Gábor Rubovszky,Seock-Ah Im,Rina Hui,Toshimi Takano,Fabrice André,Hiroyuki Yasojima,Zhenzhen Liu,Yu Ding,Liyi Jia,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia, MD, MPH
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
ByHope S. Rugo, MD,Nadia Harbeck, MD, PhD,Priya Rastogi, MD,Joyce O’Shaughnessy, MD,Frances Boyle,Javier Cortés, MD,Matthew P. Goetz, MD,Erika P. Hamilton, MD,Chiun-Sheng Huang,Elżbieta Senkus,Alexey Tryakin,Patrick Neven, MD, PhD,Jens Huober, MD,Ran Wei,Valérie André,Maria Munoz,Belen San Antonio,Ashwin Shahir,Miguel Martin, MD, PhD,Stephen Johnston
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
ByPeter Schmid, MD,Javier Cortes,Rebecca Dent, MD,Lajos Pusztai, MD, DPhil,Heather McArthur, MD, MPH,Sherko Kümmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck, MD, PhD,Masato Takahashi,Theodoros Foukakis,Marie-Ange Mouret-Reynier,Marta Ferreira,Seock-Ah Im,Fatima Cardoso,Yu Ding,Wilbur Pan,Konstantinos Tryfonidis,Joyce O’Shaughnessy, MD
The panel closes their discussion by musing on the future of HER2 mBC treatments.
A discussion on the prevalence and treatment difficulties of leptomeningeal metastases in HER2+ mBC.
The panel discusses the systemic therapy options for patients with HER2+ mBC with brain metastases before moving to whole brain radiation therapy.
Andrew Brenner, MD, presents the case of a 62-year-old patient with stage II HER2+ mBC presenting with both pulmonary and brain metastases.
Joyce O’Shaughnessy, MD, starts a conversation on managing the adverse events of tucatinib therapy in patients with HER2+ mBC with brain metastases.
The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.
Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.
Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.
Andrew Brenner, MD, explains when physicians should screen patients with HER2+ breast cancer for brain metastases.
Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.
Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.
Advertisement
Latest Updated Articles
Case Presentation: A 60-Year-Old Woman with HER2+ mBC with Brain MetastasesPublished: December 22nd 2022 | Updated:
- Leptomeningeal Metastases in HER2+ mBC
Published: January 6th 2023 | Updated:
- Systemic Therapy Before Whole Brain Radiation for HER2+ mBC with Brain Metastases
Published: January 6th 2023 | Updated:
- Screening for Brain Metastases in HER2+ Breast Cancer
Published: December 15th 2022 | Updated:
- Managing Adverse Events of Tucatinib in Patients with HER2+ mBC with Brain Metastases
Published: January 6th 2023 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup
2
Proton Beam Therapy and IMRT Confer Similar AEs and QOL in Oropharyngeal Cancer
3
Certepetide/FOLFIRINOX Displays Encouraging Preliminary Feasibility in PDAC
4
Introductions and an Overview of Multiple Myeloma Treatments
5
